Buscar
Mostrando ítems 1-10 de 213
Structural features and anticoagulant activities of a novel natural low molecular weight heparin from the shrimp Penaeus brasiliensis
(Elsevier B.V., 1999-08-05)
A natural low molecular weight heparin (8.5 kDa), with an anticoagulant activity of 95 IU/mg by the USP assay, was isolated from the shrimp Penaeus brasiliensis. the crustacean heparin was susceptible to both heparinase ...
Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients
Coronavirus disease-2019 (COVID-19) is associated with severe inflammation in mainly the lung, and kidney.
Reports suggest a beneficial effect of the use of heparin/low molecular weight heparin (LMWH) on mortality
in ...
Extensive Skin Necrosis Induced by Low-Molecular-Weight Heparin in a Patient With Systemic Lupus Erythematosus and Antiphospholipid Syndrome
(Lippincott Williams & WilkinsPhiladelphiaEUA, 2012)
US Food and Drug Administration approval of generic versions of complex biologics: implications for the practicing physician using low molecular weight heparins
(SPRINGERDORDRECHT, 2012)
Low-molecular-weight heparins (LMWHs) have shown equivalent or superior efficacy and safety to unfractionated heparin as antithrombotic therapy for patients with acute coronary syndromes. Each approved LMWH is a pleotropic ...
Combinations of low doses of unfractionated heparin and of low-molecular-weight heparin prevent experimental venous thrombosis
(Karger, 2005-01-01)
Synergism between low-molecular-weight heparin and low doses of unfractionated heparin (UH) enhancing anti-factor Xa activity and the release of tissue factor pathway inhibitor was observed. The aim of this study was to ...
Combinations of low doses of unfractionated heparin and of low-molecular-weight heparin prevent experimental venous thrombosis
(Karger, 2005-01-01)
Synergism between low-molecular-weight heparin and low doses of unfractionated heparin (UH) enhancing anti-factor Xa activity and the release of tissue factor pathway inhibitor was observed. The aim of this study was to ...
Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair
(Wiley, 2015)
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To examine the existing clinical evidence on the efficacy of prophylactic anticoagulation with direct factor Xa inhibitors versus low ...